MBAIHealthcare · Diagnostics & ResearchTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 7 of 100 as at 22 Aug 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores Check-Cap Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (92): Smaller than most of the companies we track.
Quality (1): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on MBAI, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MBAI appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 70% of US stocks
Cheaper than 7% of US stocks
Cheaper than 75% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 99% of US stocks
Higher than 11% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Check-Cap Ltd. has a market value of $11.1M and an enterprise value of $7.9M.
Trailing P/E: 1.7×.
Check-Cap Ltd. employs 85 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Check-Cap Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Check-Cap Ltd. advanced its proposed merger with physical AI company MBody AI Corp. and completed a planned 1-for-7 reverse share split.
Why it matters — The merger progress and reverse share split are key corporate actions that will reshape the company's structure and share capitalization going forward.
Check-Cap Ltd. (NASDAQ: MBAI) announced a 1-for-7 reverse share split of its ordinary shares. The announcement was made on August 7, 2026, via GlobeNewswire.
Why it matters — A reverse share split changes the number of outstanding shares and their per-share price, which can affect share liquidity, valuation metrics, and the stock's trading profile for MBAI watchers.
Check-Cap's MBody AI division secured exclusive U.S. rights to outdoor cleaning robots for the gaming and hospitality sectors across six states, expanding its addressable market beyond its existing services.
Why it matters — For MBAI watchers, this exclusive rights agreement broadens Check-Cap's addressable market into a new robotics segment across six U.S. states.
Check-Cap Ltd. has publicly filed its Form F-1 and now expects its merger with MBody AI Corp. to close within the next eight weeks.
Why it matters — This filing sets a clear timeline for the merger's completion, giving MBAI shareholders a defined period to watch for the deal to finalize.
As at 22 Aug 2026, Check-Cap Ltd. ranks 7 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (92 of 100).
No analyst covering Check-Cap Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MBAI are extrapolating price history, which says nothing about the business.
Check-Cap Ltd. is a clinical-stage medical diagnostics company based in Israel, specializing in the development of innovative capsule-based screening technology for colorectal cancer detection.
The most recent item we track (GlobeNewsWire, 13 Aug 2026): "Check-Cap (MBAI) Advances Merger with MBody AI; Reverse Share Split Effective". Check-Cap Ltd. advanced its proposed merger with physical AI company MBody AI Corp. and completed a planned 1-for-7 reverse share split.
Check-Cap Ltd. is a clinical-stage medical diagnostics company based in Israel, specializing in the development of innovative capsule-based screening technology for colorectal cancer detection. Founded in 2004, the company focuses on its proprietary C-Scan system, which includes an ingestible capsule that uses ultra-low-dose X-rays to non-invasively scan the inner lining of the colon for precancerous polyps and structural abnormalities. This capsule-based approach aims to provide patient-friendly, preparation-free colorectal screening to increase adherence and enable early intervention. The system comprises the C-Scan capsule, a disposable tracking device attached externally to the patient, and analytic software for data processing and report generation. Check-Cap's technology represents a significant advancement in non-invasive cancer diagnostics, aligning with the broader healthcare sector's focus on early detection and preventive medicine.
CEO Mr. David Lontini · 85 employees · Israel · https://check-cap.com